Literature DB >> 26168332

Heterogeneity of subordination of the IL-18/IFN-γ axis to caspase-1 among patients with Crohn's disease.

Anne Jarry1, Céline Bossard1,2, Laure Droy-Dupré1,2, Christelle Volteau3, Arnaud Bourreille4,5, Guillaume Meurette6, Jean-François Mosnier1,2, Christian L Laboisse1,2.   

Abstract

In Crohn's disease (CD), hierarchical architecture of the inflammatory network, including subordination of IL-18, an IFN-γ-inducing cytokine, to the inflammasome, have remained undeciphered. Heterogeneity among patients of such a subordination cannot be evaluated by animal models, monofactorial in their etiology and homogenous in disease progression. To address these issues, we set up an ex vivo model of inflamed mucosa explant cultures from patients with active long-standing CD. Th1 cytokine production, especially IFN-γ and IL-18, was assessed in relation with inflammation intensity. Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD. We showed a correlation between secreted IFN-γ/IL-18 levels, and caspase-1 activation, with inflammation intensity of intestinal CD mucosa explants. Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-γ response, and a heterogenous responder group, in which both IL-18 and IFN-γ responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD. These findings bring out the concept of heterogeneity of subordination of the Th1 response to inflammasome activation among CD patients. This ex vivo model should have therapeutic relevance in allowing to determine eligibility of CD patients for new targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26168332     DOI: 10.1038/labinvest.2015.89

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  34 in total

1.  Loss of interleukin-10 or transforming growth factor β signaling in the human colon initiates a T-helper 1 response via distinct pathways.

Authors:  Anne Jarry; Céline Bossard; Guillaume Sarrabayrouse; Jean-François Mosnier; Christian L Laboisse
Journal:  Gastroenterology       Date:  2011-08-10       Impact factor: 22.682

Review 2.  The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.

Authors:  Vassilis Valatas; Michael Vakas; George Kolios
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-08-29       Impact factor: 4.052

3.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells.

Authors:  T T Pizarro; M H Michie; M Bentz; J Woraratanadharm; M F Smith; E Foley; C A Moskaluk; S J Bickston; F Cominelli
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

4.  IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10.

Authors:  H Herfarth; J Schölmerich
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 5.  Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

Authors:  Warren Strober; Ivan J Fuss
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

6.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 7.  Inflammasome activation and IL-1β and IL-18 processing during infection.

Authors:  Frank L van de Veerdonk; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  Trends Immunol       Date:  2011-02-18       Impact factor: 16.687

8.  Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance.

Authors:  F Pagès; A Berger; B Henglein; B Piqueras; C Danel; F Zinzindohoue; N Thiounn; P H Cugnenc; W H Fridman
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

9.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors:  W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

10.  Inflammasome activation has an important role in the development of spontaneous colitis.

Authors:  J Zhang; S Fu; S Sun; Z Li; B Guo
Journal:  Mucosal Immunol       Date:  2014-01-29       Impact factor: 7.313

View more
  3 in total

1.  Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.

Authors:  M-A Boutet; G Bart; M Penhoat; J Amiaud; B Brulin; C Charrier; F Morel; J-C Lecron; M Rolli-Derkinderen; A Bourreille; S Vigne; C Gabay; G Palmer; B Le Goff; F Blanchard
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

Review 2.  Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm.

Authors:  Kenneth D Swanson; Evangelos Theodorou; Efi Kokkotou
Journal:  Curr Opin Gastroenterol       Date:  2018-11       Impact factor: 3.287

3.  Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa.

Authors:  Anne Jarry; Florent Malard; Chantal Bou-Hanna; Guillaume Meurette; Mohamad Mohty; Jean-François Mosnier; Christian L Laboisse; Céline Bossard
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.